Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Novel anti-BCMA immunotherapies have unprecedented responses

In this interview at the 23rd Congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, talks about B-cell maturation antigen (BCMA) as the target for multiple CAR T-cell agents for relapsed/refractory multiple myeloma (MM). These agents are proving promising, with low toxicity and high tolerability; however, there are still improvements required, and Dr Morgan ponders if these could come with the GSK-916 antibody-drug conjugate directed against BCMA.